Internal Medicine Department, University Hospital Angers, 4 rue Larrey, 49000 Angers, France; INSERM 1083, Angers, France.
Autoimmun Rev. 2015 Apr;14(4):358-62. doi: 10.1016/j.autrev.2014.12.006. Epub 2014 Dec 19.
Elective therapeutic approaches are required since recurrent thrombosis remains a major challenge in the management of antiphospholipid syndrome (APS) despite an efficient anticoagulation. Several data suggest that hydroxychloroquine (HCQ) could play a role in the prevention of thrombosis. The goal of this review is to point out the different aspects that could suggest the usefulness and the efficacy of HCQ for the prevention of thrombosis relapse in APS. By Medline research we collected important data dealing with potential anti-thrombotic effects of HCQ. The mechanisms of action of HCQ, and clinical and experimental data in systemic lupus erythematosus (SLE) and APS are discussed. As HCQ reduces the risk of thrombosis in both SLE patients and animal models of APS (1-7), and possibly decreases the titre of aPL [8], its beneficial role as a potential antithrombotic could be suggested.
尽管有效的抗凝治疗可以降低抗磷脂综合征（APS）患者的血栓复发风险，但仍需要选择治疗方法，因为血栓复发仍然是 APS 治疗的主要挑战。有几项数据表明，羟氯喹（HCQ）可能在预防血栓形成方面发挥作用。本综述的目的是指出可能提示 HCQ 对预防 APS 血栓复发有用性和疗效的不同方面。通过 Medline 研究，我们收集了有关 HCQ 潜在抗血栓作用的重要数据。讨论了 HCQ 的作用机制，以及在系统性红斑狼疮（SLE）和 APS 中的临床和实验数据。由于 HCQ 降低了 SLE 患者和 APS 动物模型的血栓形成风险（1-7），并且可能降低 aPL 的滴度[8]，因此可以提示其作为潜在抗血栓药的有益作用。
